The potential of the MAPK pathway as a therapeutic target in BRAF-mutated CRC is particularly intriguing, with the activity observed in combinations of BRAF, EGFR, and MEK inhibitors suggesting a viable strategy. The gene discussed is BRAF; the disease is colorectal carcinoma.